NewsRoom Articles - Page 127 of 153 - PsychedelicNewsWire (PNW)

TuesdayJul 07, 2020 4:00 pm

Military Puts $27M into Developing Psychedelic-Based Medicines

One of the biggest health challenges affecting the modern world is depression and substance addiction. The treatments for these conditions vary, but almost always end up in prescription pills. The U.S. military seems determined to change this, according to reports reaching media houses. Over the years, people have visited therapists and psychiatrists seeking help due to depression, anxiety, stress, and PTSD (post-traumatic stress disorder), and doctors prescribe drugs to help them with these situations. Of recent, governmental departments, one being DARPA (Defense Advanced Research Projects Agency), have started investing in researching for a new class of drugs that will enhance…

TuesdayJul 07, 2020 3:04 pm

Cybin Corp. is “One to Watch”

Cybin is a leading Canada-based mushroom life sciences company focused on psychedelic medicines and nutraceutical products The company has two operating divisions – Serenity Life Sciences (psychedelic pharmaceutical products) and Natures Journey Inc. (medicinal nutraceutical products) Members of Cybin’s experienced management team have collectively run multiple clinical trials and helped facilitate over $1 billion in pharmaceutical sales The company recently announced a strategic partnership with the Toronto Centre for Psychedelic Science Cybin is currently marketing a range of fungi-based supplements under its Journey brand aimed at breaking into the global non-psychedelic legal supplement market, which is valued at $25 billion…

TuesdayJul 07, 2020 10:00 am

Clinical Trial on Treating Cluster Headaches Using LSD Underway

A Phase 2 clinical trial on how LSD can be used to treat cluster headaches is underway in Switzerland. The trial is being conducted at Liechti Lab at University Hospital Basel. Patients willing to participate in this study were recruited in January this year and the trial is now underway. Cluster headaches are also referred to as “suicide headaches” since the pain they cause is so severe that many patients with this condition develop suicidal tendencies during an episode. Cluster headaches have also been variously described as the most painful condition that anyone can ever suffer from. The pain caused…

MondayJul 06, 2020 3:00 pm

Psilocybin Ballot Initiative Likely in Colorado After Voters Show Strong Support

RBI Strategies & Research conducted a poll in Colorado between March 17 and 19 this year, and the findings of that poll are out. The survey results have given activists the impetus that they need to consider putting a psilocybin ballot measure on the 2022 ballot. This positive news comes approximately one year after the city of Denver made history as the first U.S. city to decriminalize the possession of “magic mushrooms.” This milestone was reached after the tireless work done by “Decriminalize Denver” paid off. Now the recent survey conducted by RBI has provided more good news for the…

MondayJul 06, 2020 10:00 am

Phase 1 Clinical Trial Planned to Evaluate DMT

Mind Medicine (NEO: MMED) (OTCQB: MMEDF) (“MindMed”) recently announced that it was providing funding for a Phase 1 clinical trial aimed at evaluating the main psychotropic active ingredient dimethyltryptamine (“DMT”) found in ayahuasca. This clinical trial is slated to begin in the fourth quarter of this year. DMT occurs naturally and is the primary reason why the indigenous shamanic practitioners in the Amazon use ayahuasca in their ceremonies. However, DMT quickly triggers its psychoactive effects and these effects also wear off a lot sooner than those of other psychedelic ingredients like LSD and psilocybin. When DMT is administered as an…

ThursdayJul 02, 2020 3:45 pm

Activists Say Oregon Psilocybin Ballot Measure Obtained Enough Signatures for November Poll

Activists behind an initiative to legalize magic (psilocybin) mushrooms in Oregon for medicinal purposes have announced that they gathered a lot more than the required number of voter signatures in order for the measure to qualify for the polls in November. While Oregon’s Secretary of State hasn’t verified all those signatures, the advocates behind the “Yes on IP34” say that according to their independent audit, the campaign exceeded the minimum number of required signatures before the deadline on July 2. Their confidence may not be misplaced, given that the office of the Secretary of State had confirmed that the first…

ThursdayJul 02, 2020 10:00 am

3 Novel Ways in Treating Addiction

Approximately 40 million people in the U.S. suffer from substance abuse disorders (SAD), and the number is expected to grow as other forms of addiction, such as gambling and video games, take a bigger toll on the population. Currently, there are about eight drugs to treat addiction, and it isn’t surprising that these aren’t always helpful in treating patients since the people with SAD exhibit various symptoms which may not always respond to the existing pharmaceutical options. Consequently, there is a huge need to think outside the box and come up with novel ways to treat SAD. Here are three…

WednesdayJul 01, 2020 3:15 pm

New Poll Shows Most Canadians Support Legalizing Psilocybin for Terminally Ill Patients

A new poll conducted in June this year shows that most Canadians support the legalization of psilocybin, the active ingredient in magic mushrooms (shrooms) for the treatment of terminally ill patients. Currently, magic mushrooms are listed in Schedule III of the Controlled Drugs and Substances Act in Canada. This makes the compound inaccessible for therapeutic purposes. This categorization has remained even if a lot of research from globally respected research entities at New York University, Johns Hopkins, UCLA and Kings College London, among others, shows the irrefutable potential and safety of psychedelics in treating a variety of conditions. TheraPsil, a…

WednesdayJul 01, 2020 10:00 am

New Product Could Flip the Switch on Bad LSD Trips

When you talk to a number of people who have ever consumed magic mushrooms and other plant-based psychedelic substances, you will inevitably encounter stories of “bad trips” characterized by feelings of entrapment, mild anxiety, terror, alienation and other such unpleasant effects. The risk of these “bad trips” scares a lot of people away from using psychedelics, and one psychedelic medicine company has come up with an invention that could neutralize and stop a bad LSD trip in its tracks. Mind Medicine (NEO: MMED) (OTCQB: MMEDF) (“MindMed”), together with the Liechti Laboratory found at Basel University Hospital in Switzerland, are the…

TuesdayJun 30, 2020 3:30 pm

Psychedelic Stocks: Why Your Investment Portfolio Should Be Teeming With Them

This may sound unbelievable, but, despite the raging COVID-19 pandemic, great investment opportunities are still out there. By investment, we are not referring to companies which specialize in bulk-packaging toilet paper or churning out millions of gallons of sanitizer. Psychedelic medicine stocks are what we are talking about, and here are some compelling reasons why your investment portfolio needs to have these medicines. You’d Be Getting in Early Lots of people who invested in marijuana stocks are regretting their decision for one key reason; they joined the fray late in the game when marijuana stocks had nearly peaked, and the…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000